Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 24;12(8):1124.
doi: 10.3390/genes12081124.

Advances with Long Non-Coding RNAs in Alzheimer's Disease as Peripheral Biomarker

Maria Garofalo  1   2 , Cecilia Pandini  1   2 , Daisy Sproviero  1 , Orietta Pansarasa  1 , Cristina Cereda  1 , Stella Gagliardi  1
Affiliations
Review

Advances with Long Non-Coding RNAs in Alzheimer's Disease as Peripheral Biomarker

Maria Garofalo et al. Genes (Basel). .

Abstract

One of the most compelling needs in the study of Alzheimer's disease (AD) is the characterization of cognitive decline peripheral biomarkers. In this context, the theme of altered RNA processing has emerged as a contributing factor to AD. In particular, the significant role of long non-coding RNAs (lncRNAs) associated to AD is opening new perspectives in AD research. This class of RNAs may offer numerous starting points for new investigations about pathogenic mechanisms and, in particular, about peripheral biomarkers. Indeed, altered lncRNA signatures are emerging as potential diagnostic biomarkers. In this review, we have collected and fully explored all the presented data about lncRNAs and AD in the peripheral system to offer an overview about this class of non-coding RNAs and their possible role in AD.

Keywords: Alzheimer’s disease; biomarkers; long non-coding RNA; peripheral system.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Angelucci F., Cechova K., Valis M., Kuca K., Zhang B., Hort J. MicroRNAs in Alzheimer’s disease: Diagnostic markers or therapeutic agents? Front. Pharmacol. 2019;10:1–9. doi: 10.3389/fphar.2019.00665. - DOI - PMC - PubMed
    1. Ramakrishna S., Muddashetty R.S. Emerging Role of microRNAs in Dementia. J. Mol. Biol. 2019;431:1743–1762. doi: 10.1016/j.jmb.2019.01.046. - DOI - PubMed
    1. Hu Y.K., Wang X., Li L., Du Y.H., Ye H.T., Li C.Y. MicroRNA-98 induces an Alzheimer’s disease-like disturbance by targeting insulin-like growth factor 1. Neurosci. Bull. 2013;29:745–751. doi: 10.1007/s12264-013-1348-5. - DOI - PMC - PubMed
    1. Fang M., Wang J., Zhang X., Geng Y., Hu Z., Rudd J.A., Ling S., Chen W., Han S. The miR-124 regulates the expression of BACE1/β-secretase correlated with cell death in Alzheimer’s disease. Toxicol. Lett. 2012;209:94–105. doi: 10.1016/j.toxlet.2011.11.032. - DOI - PubMed
    1. Hansen T.B., Jensen T.I., Clausen B.H., Bramsen J.B., Finsen B., Damgaard C.K., Kjems J. Natural RNA circles function as efficient microRNA sponges. Nature. 2013;495:384–388. doi: 10.1038/nature11993. - DOI - PubMed

Publication types